CWA Asset Management Group LLC Acquires 5,017 Shares of Organon & Co. (NYSE:OGN)

CWA Asset Management Group LLC lifted its holdings in shares of Organon & Co. (NYSE:OGN) by 27.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 23,596 shares of the company’s stock after purchasing an additional 5,017 shares during the period. CWA Asset Management Group LLC’s holdings in Organon & Co. were worth $352,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in OGN. Versant Capital Management Inc grew its stake in shares of Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after buying an additional 1,324 shares during the last quarter. Garden State Investment Advisory Services LLC bought a new position in Organon & Co. during the 3rd quarter worth approximately $203,000. Franklin Resources Inc. grew its position in Organon & Co. by 3.9% during the 3rd quarter. Franklin Resources Inc. now owns 344,138 shares of the company’s stock worth $6,229,000 after acquiring an additional 13,029 shares during the last quarter. Tidal Investments LLC increased its stake in Organon & Co. by 10.6% in the 3rd quarter. Tidal Investments LLC now owns 76,525 shares of the company’s stock worth $1,464,000 after purchasing an additional 7,330 shares during the period. Finally, Optimist Retirement Group LLC purchased a new position in shares of Organon & Co. in the third quarter worth $1,974,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Up 1.7 %

NYSE OGN opened at $15.99 on Thursday. The stock has a market cap of $4.12 billion, a P/E ratio of 3.17, a price-to-earnings-growth ratio of 0.81 and a beta of 0.76. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The stock has a 50 day simple moving average of $15.46 and a two-hundred day simple moving average of $18.46. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.78 EPS. On average, analysts forecast that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Analyst Ratings Changes

Separately, Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.